Originalarbeiten

2011

125.Januschowski K, Mueller S, Spitzer MS, Lueke M, Bartz-Schmidt KU, Szurman P. The effects of the intraocular dye brilliant blue G (BBG) mixed with varying concentrations of glucose on retinal function in an isolated perfused vertebrate retina. Graefes Arch Clin Exp Ophthalmol 2011; in press [Epub ahead of print] [IF 2.102]
124.Wilke R, Gabel VP, Sachs H, Bartz Schmidt KU, Gekeler F, Besch D, Szurman P, Stett A, Wilhelm B, Peters T, Harscher A, Greppmaier U, Kibbel S, Benav H, Bruckmann A, Stingl K, Kusnyerik A, Zrenner E. Spatial Resolution and Perception of Patterns Mediated by a Subretinal16-Electrode Array in Patients Blinded by Hereditary Retinal Dystrophies. Invest Ophthalmol Vis Sci 2011 [Epub ahead of print] [IF 3.582]
123.Saygili O, Szurman P, Gieselmann S, Deuter C, Spitzer MS, Thaler S, Bartz-Schmidt KU, Yoeruek E. Klinische Ergebnisse nach Kataraktchirurgie bei Patienten mit Behçet Erkrankung. Klin Monbl Augenheilkd 2011 [Epub ahead of print] [IF 0.576]
122.Zrenner E, Bartz-Schmidt KU, Benav H, Besch D, Bruckmann A, Gabel VP, Gekeler F, Greppmaier U, Harscher A, Kibbel S, Koch J, Kusnyerik A, Peters T, Stingl K, Sachs H, Stett A, Szurman P, Wilhelm B, Wilke R. Subretinal electronic chips allow blind patients to read letters and combine them to words. Proc Biol Sci 2011; 278: 1489-1497 [IF 4.857]
121.Petermeier K, Messias A, Gekeler F, Szurman P. Effect of +3.00 diopter and +4.00 diopter additions in multifocal intraocular lenses on defocus profiles, patient satisfaction, and contrast sensitivity. J Cataract Refract Surg 2011; 37 :720-726 [2.745]
120.Petermeier K, Frank C, Gekeler F, Spitzer MS, Messias A, Szurman P. Influence of the pupil size on visual quality and spherical aberration after implantation of the Tecnis 1-piece intraocular lens. Br J Ophthalmol 2011; 95: 42-45 [2.917]
119.Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, Spital G, Heimann H, Meyer CH; Retinal Vein Occlusion Study Group. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2011; 249: 183-192 [IF 2.102]
118.Spitzer MS, Ziemssen F, Yörük E, Bartz-Schmidt KU, Schultheiß M, Szurman P. Primär konservierungsmittelfreies Triamcinolon im Vergleich zu aufgereinigten Triamcinolonpräparaten. Klin Monbl Augenheilkd 2011; 228: 626-630 [IF 0.576]

2010

117.Jaissle GB, May CA, van de Pavert SA, Wenzel A, Claes-May E, Giessl A, Szurman P, Wolfrum U, Wijnholds J, Fischer MD, Humphries P, Seeliger MW. Bone spicule pigment formation in retinitis pigmentosa: insights from a mouse model. Graefes Arch Clin Exp Ophthalmol 2010; 248: 1063-1070. Erratum in: Graefes Arch Clin Exp Ophthalmol 2010; 248: 1365. Fisher, MD [IF 2.102]
116.Gekeler F, Kopp S, Sachs H, Besch D, Greppmaier U, Zrenner E, Bartz-Schmidt KU, Szurman P. Visualization of active subretinal implants with external connections by high-resolution computed tomography. Br J Ophthalmol 2010; 94: 843-847 [IF 2.917]
115.Lüke M, Januschowski K, Lüke J, Grisanti S, Szurman P, Dietz K, Kampik A, Bartz-Schmidt KU, Eibl-Lindner KH. The safety profile of alkylphosphocholines in the model of the isolated perfused vertebrate retina. Graefes Arch Clin Exp Ophthalmol 2010; 248: 511-518 [IF 2.102]
114.Yoeruek E,  Deuter C, Gieselmann S, Saygili O, Spitzer MS,  Tatar O, Bartz-Schmidt KU,  Szurman P. Long term visual acuity and its predictors after cataract surgery in patients with uveitis. Eur J Ophthalmol 2010; 20: 694-6701 [IF 1.010]
113.Lüke M, Januschowski K, Tura A, Lüke J, Nassar K, Lüke C, Schneider T, Szurman P, Grisanti S, Bartz-Schmidt KU. The effects of pegaptanib sodium on retinal function in isolated perfused vertebrate retina. Curr Eye Res 2010; 35: 248-254 [IF 1.519]
112.Szurman P, Petermeier K, Aisenbrey S, Spitzer MS, Jaissle G. Z-suture - A new knotless technique for transscleral suture fixation of intraocular implants. Br J Ophthalmol 2010; 94: 167-169 [IF 2.917]
111.Beutel J, Peters S, Lüke M, Aisenbrey S, Szurman P, Spitzer MS, Yoeruek E; the Bevacizumab Study Group, Grisanti S. Bevacizumab as adjuvant for neovascular glaucoma. Acta Ophthalmol 2010; 88: 103-109 [IF 2.441]
110.Yoeruek E, Tatar O, Spitzer MS, Saygili O, Biedermann T, Bartz-Schmidt KU, Szurman P. Effects of Bevacizumab on Apoptosis, Na+/K+-ATPase and ZO-1-Expression on Cultured Corneal Endothelial Cells. Ophthalmic Res 2010; 44: 43-49 [IF 1.317]

2009

109.Spitzer MS, Kaczmarek RT, Yoeruek E, Petermeier K, Wong D, Heimann H, Jaissle GB, Bartz-Schmidt KU, Szurman P. The distribution, release kinetics and biocompatibility of triamcinolone injected and dispersed in silicone oil. Invest Ophthalmol Vis Sci 2009; 50: 2337-2343 [IF 3.582]
108.Petermeier K, Gekeler F, Spitzer MS, Szurman P. Implantation of the multifocal ReSTOR apodized diffractive intraocular lens in adult anisometropic patients with mild to moderate amblyopia. Br J Ophthalmol 2009; 93: 1269-1301 [IF 2.917]
107.Petermeier K, Gekeler F, Messias A, Spitzer MS, Haigis W, Szurman P. Intraocular lens power calculation in highly myopic eyes implanted with the Alcon AcrySof® MA60MA. J Cataract Refract Surg 2009; 35: 1575-1581 [2.745]
106.Lüke M, Januschowski K, Lüke J, Peters S, Wirtz N, Yörük E, Lüke Ch, Bartz-Schmidt KU, Grisanti S, Szurman P. The effects of ranibizumab (Lucentis®) on retinal function in isolated perfused vertebrate retina. Br J Ophthalmol 2009; 2009; 93: 1396-1400 [IF 2.917]
105.Spitzer MS; Chirambo T, Kayange P, Szurman P, Yoeruek E, Bartz-Schmidt KU, Batumba HN. Der Einfluss der HIV-Pandemie auf die Inzidenz maligner Augentumoren im südlichen Malawi (Blantyre). Ophthalmologe 2009; 106: 813-818 [IF 1.133]
104.Petermeier K, Messias A, Gekeler F, Spitzer MS, Szurman P. Outcomes of the AcrySof ReSTOR® IOL in myopes, emmetropes, and hyperopes. J Refract Surg 2009; 25: 1103-1109 [IF 1.914]
103.Szurman P, Frank C, Kaczmarek RT, Spitzer MS. Glaskörperersatz als Möglichkeit zur protrahierten Freisetzung von Medikamenten im Glaskörper. Klin Monatsbl Augenheilkd 2009; 226: 718-724 [IF 0.576]
102.Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P. One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009; 247; 27-33 [IF 2.102]
101.Tatar O, Adam A, Shinoda K, Kaiserling E, Boeyden V, Claes C, Eckardt C, Eckert T, Pertile G, Scharioth GB, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Early effects of intravitreal triamcinolone acetonide on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2009; 127: 275-281 [IF 3.859]
100.Neuhann IM, Neuhann TF, Szurman P, Koerner S, Rohrbach JM, Bartz-Schmidt KU. Clinicopathological correlation of 3 patterns of calcification in a hydrophilic acrylic intraocular lens. J Cataract Refract Surg 2009; 35: 593-597 [IF 2.745]
99.Jaissle GB, Ulmer A, Henke-Fahle S, Aisenbrey S, Fierlbeck G, Bartz-Schmidt KU, Szurman P. Intraokulares Bevacizumab als palliative Therapie bei Melanommetastasen-assoziiertem rubeotischen Sekundärglaukom. Klin Monatsbl Augenheilkd 2009; 226: 70-72 [IF 0.576]
98.Tatar O, Shinoda K, Kaiserling E, Claes C, Eckardt C, Eckert T, Boeyden V, Pertile G, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Implications of bevacizumab on vascular endothelial growth factor and endostatin in human choroidal neovascularization. Br J Ophthalmol 2009; 93: 159-165 [IF 2.917]
97.Peters S, Tatar O, Spitzer MS, Szurman P, Aisenbrey S, Lüke M, Adam A, Yoeruek E, Grisanti S. Analysis of the neuronal marker protein gene product 9.5 in internal limiting membranes after indocyanine-green assisted peeling. Retina 2009; 29: 243-247  [IF 3.478]
96.Feudner EM, Engel C, Neuhann IM, Petermeier K, Bartz-Schmidt KU, Szurman P. Virtual reality training improves wet-lab performance of capsulorhexis: results of a randomized, controlled study. Graefes Arch Clin Exp Ophthalmol 2009; 247: 955-963 [IF 2.102]
95.Yoeruek E, Saygili O Spitzer MS, Tatar O, Bartz-Schmidt KU, Szurman P. Human anterior lens capusle as a carrier matrix for cultivated human corneal endothelial cells. Cornea 2009; 28: 416-420 [IF 1.853]
94.Frank C, Szurman P, Peters S, Zierhut M, Spitzer MS. Spätes Rezidiv einer Spender-assoziierten Endophthalmitis durch Candida glabrata nach Keratoplastik. Klin Monatsbl Augenheilkd 2009; 26: 510-511 [IF 0.576]
93.Kaczmarek R, Szurman P, Misiuk-Hojło M, Grzybowski A. Antiproliferative effects of preservative-free triamcinolone acetonide on cultured human retinal pigment epithelial cells. Med Sci Monit 2009; 15: 227-231 [IF 1.514]

2008

92.Besch D, Sachs H, Szurman P, Gülicher D, Wilke R Dr, Reinert S, Zrenner E, Bartz-Schmidt KU, Gekeler F.  Extraocular surgery for implantation of an active subretinal viusal prosthesis with external connections: feasibility and outcome in seven patients; Br J Ophthalmol 2008; 92: 1361-1368 [IF 2.859]
91.Yoeruek E, Spitzer MS, Saygili O, Tatar O, Biedermann T, Yoeruek E, Bartz-Schmidt KU, Szurman P. Comparison of in vitro safety profiles of Vancomycin and cefuroxime on human corneal endothelial cells for intracameral use. J Cataract Refract Surg 2008; 34; 2139-2145 [IF 2.508]
90.Zhu Q, Ziemssen F, Henke-Fahle S, Tatar O, Szurman P, Aisenbrey S, Schneiderhan-Marra N, Xu X, Grisanti S. Vitreous levels of bevacizumab and vascular endothelial growth factor-A in patients with choroidal neovascularization. Ophthalmology 2008; 115; 1750-1755 [IF 5.296]
89.Yoeruek E, Spitzer MS, Tatar O, Biedermann T, Grisanti S, Lüke M, Bartz-Schmidt KU, Szurman P. Toxic effects of recombinant tissue plasminogen activator on human corneal endothelial cells. Invest Ophthalmol Vis Sci 2008; 49: 1392-1397 [IF 3.528]
88.Jaissle GB, Ulmer A, Henke-Fahle S, Fierlbeck G, Bartz-Schmidt KU, Szurman P. Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol 2008; 144: 525-527 [IF 3.402]
87.Lüke M, Januschowski K, Beutel J, Lüke C, Grisanti S, Peters S, Kirchhof B, Bartz-Schmidt KU, Szurman P. The electrophysiological effects of Brilliant Blue G in the model of the isolated perfused vertebrate retina. Graefes Arch Clin Exp Ophthalmol 2008; 246: 817-822 [IF 1.770]
86.Yoeruek E, Szurman P, Tatar O, Weckerle P, Wilhelm H. Anterior ischemic optic neuropathy due to giant cell arteritis with normal inflammatory markers. Graefes Arch Clin Exp Ophthalmol 2008; 246: 913-915 [IF 1.770]
85.Spitzer MS, Szurman P, Bartz-Schmidt KU. Correspondence: Intravitreal bevacizumab in postoperative pseudophakic cystoid macular edema: Does it really work? J Cataract Refract Surg 2008; 34: 880-881 [IF 2.508]
84.Szurman P. August consultation 4. J Cataract Refract Surg 2008; 34: 1234 [IF 2.508]
83.Jaissle GB, Bartz-Schmidt KU, Szurman P. Opticus-Atrophie nach epiretinalen Traimcinolon-Ablagerungen nach ILM-Peeling. Ophthalmologe 2008; 205: 575-577 [IF 1.133]
82.Tatar O, Yoeruek E, Szurman P, Bartz-Schmidt KU; Tübingen Bevacizumab Study Group, Adam A, Shinoda K, Eckardt C, Boeyden V, Claes C, Pertile G, Scharioth GB, Grisanti S.  Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008;126: 782-790 [IF 3.242]
81.Lüke M, Januschowski K, Beutel J, Warga M, Grisanti S, Peters S, Schneider T, Lüke C, Bartz-Schmidt KU, Szurman P. The effects of triamcinolone crystals on retinal function in a model of isolated perfused vertebrate retina. Exp Eye Res 2008; 87: 22-29 [IF2.579]
80.Spitzer MS, Ziemssen F, Gelisken F, Bartz-Schmidt KU, Szurman P. Treatment of age-related macular degeneration: Focus on ranibizumab. Clin Ophthalmol 2008;2: 1-14 [IF 1.031]
79.Spitzer MS, Yoeruek E, Kaczmarek RT, Sierra A, Aisenbrey S, Grisanti S, Bartz-Schmidt KU, Szurman P. Sodium hyaluronate gels as a drug release system for corticosteroids: Release kinetics and antiproliferative potential for glaucoma surgery. Acta Ophthalmol Scand 2008; 8: 842-848 [IF 2.138]
78.Spitzer MS, Batumba NH, Chirambo T, Kayange P, Szurman P. Ocular surface squamous neoplasia as first apparent manifestation of HIV infection in Malawi. Clin Exp Ophthalmol 2008; 36: 422-425 [IF 1.347]
77.Tatar O, Shinoda K, Kaiserling E, Pertile G, Eckardt C, Mohr A, Yoeruek E, Szurman P, Bartz-Schmidt KU, Grisanti S. Early effects of triamcinolone acetonide on vascular endothelial growth factor and endostatin in human choroidal neovascularization. Arch Ophthalmol 2008; 126: 193-199 [IF 3.242]
76.Feudner EM, Gelisken F, Szurman P. Asymmetrisch ausgeprägte kristalline retinale Ablagerungen. Ophthalmologe 2008; 105: 384-388 [IF 1.133]
75.Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, Bartz-Schmidt KU, Szurman P. Tübingen Bevacizumab Study Group: Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol Scand 2008; 86: 322-387 [IF 2.138]
74.Ziemssen F, Zhu Q, Peters S, Grisanti S, El Wardani M, Szurman P, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group, Ziemssen T. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2008; 28: 101-109
73.Yoeruek E, Deuter CM, Szurman P, Tatar O, Zierhut M. Varicella-Zoster-Virus-assoziierte Skleromalazie. Ophthalmologe 2008; 105: 480-484 [IF 1.133]
72.Spitzer MS, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. J Cataract Refract Surg 2008; 34: 70-75 [IF 2.508]

2007

71.Heiduschka P, Fietz H, Hofmeister S, Schultheiss S, Mack AF, Peters S, Ziemssen F, Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U; Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007; 48: 2814-2823 [IF 3.528]
70.Beutel J, Greulich L, Lueke M, Ziemssen F, Szurman P, Bartz-Schmidt KU, Grisanti S. Inner Limiting Membrane as membranous support in RPE sheet-transplantation. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1469-1473 [IF 1.59]
69.Lüke M, Januschowski K, Warga M, Beutel J, Leitritz M, Gelisken F, Grisanti S, Schneider T, Lüke C, Bartz-Schmidt KU. Szurman P. The retinal tolerance to bevacizumab in co-application with a recombinant tissue plasminogen activator. Br J Ophthalmol 2007; 91: 1077-1082 [IF 2.689]
68.Gelisken F, Voelker M, Schwabe R, Besch D, Aisenbrey S, Szurman P, Grisanti S, Herzau V, Bartz-Schmidt KU. Full Macular Translocation versus Photodynamic Therapy with Verteporfin in Treatment of Neovascular Age-related Macular Degeneration: 1 Year Results of a prospective, controlled, randomised Pilot-Trial (FMT-PDT). Graefes Arch Clin Exp Ophthalmol 2007, 245: 1085-1095 [IF 1.59]
67.Lüke M, Szurman P, Schneider T, Lüke C. Effects of the phosphodiesterase type V inhibitor sildenafil on human retinal function in vitro. Graefes Arch Clin Exp Ophthalmol 2007; 245: 1211-1215 [IF 1.59]
66.Peters S, Heiduschka P, Julien S, Ziemssen F, Fietz H, Bartz-Schmidt KU; Tübingen Bevacizumab Study Group, Schraermeyer U. Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007; 143: 995-1002 [IF 2.628]
65.Yoeruek E, Spitzer MS, Tatar O, Aisenbrey S, Bartz-Schmidt KU, Szurman P. Safety profile of bevacizumab (Avastin®) on cultured human corneal cells. Cornea. 2007; 26: 977-982 [IF 1.776]
64.Yoeruek E, Jaegle H, Lüke M, Grisanti S, Warga M, Krott R, Spitzer MS, Tatar O, Bartz-Schmidt KU, Szurman P. Safety profile of a taurine containing irrigation solution (AcriPurRet®) in pars plana vitrectomy. Retina 2007; 27: 1286-1291 [IF 3.088]
63.Aisenbrey S, Ziemssen F, Völcker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz-Schmidt KU. Intravitreal bevacizumab (Avastin) for occult choroidale neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 941-948 [IF 1.59]
62.Jaissle GB, Szurman P, Rohrbach JM, Gelisken F, Bartz-Schmidt KU. A case of cutaneous melanoma metastatic to the vitreous cavity: Possible pathomechanism and review of the literature. Graefes Arch Clin Exp Ophthalmol 2007; 245: 733-740 [IF 1.59]
61.Peters S, Julien S, Heiduschka P, Grisanti S, Ziemssen F, Adler M, Schraermeyer U, Bartz-Schmidt KU; The Tuebingen Bevacizumab Study Group. Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells. Br J Ophthalmol 2007; 91: 827-831 [IF 2.689]
60.Szurman P, Heiligenhaus A, Hettlich HJ, Dick HB, Kohnen T. Kataraktchirurgie bei Uveitis im Kindesalter. Klin Monatsbl Augenheilkd 2007; 224: 532-537 [IF 0.576]
59.Aisenbrey S, Gelisken F, Szurman P, Bartz-Schmidt KU. Surgical treatment of peripapillary choroidal neovascularization. Br J Ophthalmol 2007; 91: 1027-1030 [IF 2.689]
58.Spitzer MS, Szurman P, Aisenbrey S, Rohrbach JM. Rapid development of band keratopathy of corneal graft after treatment with intracameral recombinant tissue plasminogen activator for postoperative fibrin reaction. Eur J Ophthalmol 2007; 17: 433-436 [IF 1.018]
57.Szurman P, Roters S, Grisanti S, Aisenbrey S, Rohrbach JM, Warga M, Gelisken F, Spitzer MS, Bartz-Schmidt KU. Primary silicone oil endotamponade in the management of severe intraocular foreign body injuries: an eight-year follow-up. Retina 2007; 27: 304-311 [IF 3.088]
56.Szurman P, Kaczmarek R, Jaissle GB, Grisanti S, Lüke M, Spitzer MS, Heide PE, Bartz-Schmidt KU. Influence of different purification techniques on triamcinolone yield and particle size spectrum. Graefes Arch Clin Exp Ophthalmol 2007; 245: 689-696 [IF 1.59]
55.Petermeier K, Szurman P. Subjektive und objektive Ergebnisse nach Implantation der apodisiert diffraktiven AcrySof ReSTOR. Ophthalmologe 2007; 104: 399-408 [IF 0.791]
54.Ziemssen F, Lüke M, Messias A, Beutel J, Tatar O, Zrenner E, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 2007; 28: 101-109
53.Tatar O, Adam A, Shinoda K, Yoeruek E, Szurman P, Bopp S, Eckardt C, Bartz-Schmidt KU, Grisanti S. Influence of Verteporfin Photodynamic Therapy on Inflammation in Human Choroidal Neovascular Membranes secondary to Age-Related Macular Degeneration. Retina 2007; 27: 713-723 [IF 3.088]
52.Aisenbrey S, Bartz-Schmidt KU, Walter P, Hilgers RD, Ayertey H, Szurman P, Thumann G. Long-term follow-up of macular translocation with 360 degrees retinotomy for exudative age-related macular degeneration. Arch Ophthalmol 2007; 125: 1367-1372 [IF 2.984]
51.Peters S, Altvater A, Bopp S, Vonthein R, Szurman P, Spitzer MS, Warga M, Lüke M, Bartz-Schmidt KU, Grisanti S. Systematic evaluation of ICG and Trypan Blue related effects on ARPE-19 cells in vitro. Exp Eye Res 2007; 85: 880-889 [IF 2.651]
50.Spitzer MS, Sierra A, Yoeruek E, Wallenfels-Thilo B, Schraermeyer U, Spitzer B, Bartz-Schmidt KU, Szurman P. Comparative antiproliferative and cytotoxic profile of bevacizumab (AvastinTM), pegaptanib (MacugenTM) and ranibizumab (LucentisTM) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007 ; 245 : 1837-1842 [IF 1.59]
49.Szurman P, Sierra A, Kaczmarek R, Jaissle GB, Wallenfels-Thilo B, Grisanti S, Lüke M, Bartz-Schmidt KU, Spitzer MS. Different biocompatibility of crystalline triamcinolone deposits on retinal cells in vitro and in vivo. Exp Eye Res 2007, 85: 44-53 [IF 2.651]
48.Rohrbach JM, Grüb M, Szurman P. Einseitige, rezidivierende Trübung des Hornhautepithels. Ophthalmologe 2007; 223: 72-74 [IF 0.791]
47.Lüke M, Krott R, Warga M, Szurman P, Grisanti S, Bartz-Schmidt KU, Schneider T, Lüke C. Effects of the protein tyrosine kinase inhibitor genistein and taurine on retinal function in isolated superfused retina. Graefes Arch Clin Exp Ophthalmol 2007; 245 : 242-248 [IF 1.59]
46.Spitzer MS, Szurman P, Rohrbach JM, Aisenbrey S. Beidseitiges kongenitales Glaukom bei einem Kind mit Cutis marmorata telangiectatica congenita. Klin Monatsbl Augenheilkd 2007; 224: 66-69 [IF 0.576]
45.Gekeler F, Szurman P, Grisanti S, Weiler U, Claus R, Greiner TO, Volker M, Kohler K, Zrenner E, Bartz-Schmidt KU. Compound subretinal prostheses with extra-ocular parts designed for human trials: successful long-term implantation in pigs. Graefes Arch Clin Exp Ophthalmol 2007; 245: 230-241 [IF 1.59]
44.Jaissle GB, Szurman P, Völker M, Bartz-Schmidt KU. Epiretinal deposit of triamcinolone acetonide at the posterior pole after intravitreal injection. Ophthalmic Surg Lasers Imaging 2007; 38: 238-241 [IF 1.432]
43.Szurman P, Petermeier K, Grisanti S, Jaissle GB, Bartz-Schmidt KU. A new small-incision technique for injector implantation of transsclerally sutured foldable lenses. Ophthalmic Surg Lasers Imaging 2007; 38: 76-80 [IF 1.432]

2006

42.Spitzer MS, Wallenfels-Thilo B, Sierra A, Yoeruek E, Peters S, Henke-Fahle S, Bartz-Schmidt KU, Szurman P. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006; 90: 1316-1321 [IF 2.524]
41.Lüke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider T, Lüke C, Partsch M, Bartz-Schmidt KU, Szurman P. Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 2006; 90: 1178-1182 [IF 2.524]
40.Szurman P, Warga M, Bartz-Schmidt KU. Correspondence: Reply to Liu DTL, Chi-Lai L, Lee VYW, Lam DSC. Experimental implantation and long-term testing of an Intraocular Vision Aid in rabbits. Arch Ophthalmol 2006; 124: 610 [IF 3.206]
39.Szurman P, Roters S, Grisanti S, Aisenbrey S, Schraermeyer U, Lüke M, Bartz-Schmidt KU, Thumann G. Ultrastructural changes following artificial retinal detachment with modified retinal adhesion. Invest Ophthalmol Vis Sci 2006; 47: 4983-4989 [IF 3.766]
38.Szurman P, Petermeier K, Jaissle GB, Spitzer MS, Bartz-Schmidt, KU. Injektorimplantation sklerafixierter Faltlinsen. Ophthalmologe 2006; 103: 1020-1026 [IF 0.762]
37.Rohrbach JM, Szurman P, El-Wardani ME, Grüb M. Zur Häufigkeit der exzessiven Verdickung der epithelialen Basalmembran beim Keratokonus. Klin Monatsbl Augenheilkd 2006; 223: 889-893 [IF 0.679]
36.Karim-Zade K, Mielke J, Besch D, Szurman P, Ernemann U, Herzau V. Choroidales Effusionssyndrom nach Embolisation einer indirekten Sinus-cavernosus-Fistel über die V. ophthalmica superior. Ophthalmologe 2006; 103: 609-611 [IF 0.762]
35.Szurman P, Kaczmarek R, Spitzer MS, Jaissle GB, Decker P, Grisanti S, Henke-Fahle S, Aisenbrey S, Bartz-Schmidt KU. Differential toxic effect of dissolved triamcinolone and its crystalline deposits on cultured human retinal pigment epithelium (ARPE19) cells. Exp Eye Res 2006; 83: 584-592 [IF 2.776]
34.Ziemssen F, Warga M, Neuhann IM, Leitritz M, Biester S, Grisanti S, Bartz-Schmidt KU; The Tuebingen Bevacizumab Study Group. Does intravitreal injection of bevacizumab have an effect on the blood-aqueous barrier function? Br J Ophthalmol 2006; 90: 922 [IF 2.524]
33.Szurman P, Warga M, Grisanti S, Roters S, Rohrbach JM, Aisenbrey S, Kaczmarek RT, Bartz-Schmidt KU. Sutureless amniotic membrane fixation using fibrin glue for ocular surface reconstruction in a rabbit model. Cornea 2006; 25:460-466 [IF 1.708]
32.Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU; Tuebingen Bevacizumab Study Group. Intracameral bevacizumab for iris rubeosis. Am J Ophthalmol 2006; 142: 158-160 [IF 2.468]
31.Aisenbrey S, Lafaut BA, Szurman P, Hilgers R-D, Esser P, Walter P, Bartz-Schmidt KU, Thumann G. Iris pigment epithelial translocation in the treatment of exudative macular degeneration: A three-year follow-up. Arch Ophthalmol 2006; 124:183-188 [IF 3.206]
30.Rohrbach JM, Süsskind D, Szurman P, Siepmann K. Hornhautstaphylom-Vorderkammeragenesie-Mikrophakie-Syndrom. Klin Monatsbl Augenheilkd 2006; 223: 168-75 [IF 0.679]
29.Jaissle GB, Ziemssen F, Petermeier K, Szurman P, Ladewig M, Gelisken F, Völker M, Holz FG, Bartz-Schmidt KU. Bevacizumab zur Therapie des sekundären Makulaödems nach venösen Gefäßverschlüssen. Ophthalmologe 2006; 103: 471-475 [IF 0.762]

2005

28.Szurman P, Warga M, Roters S, Grisanti S, Heimann U, Aisenbrey S, Rohrbach JM, Sellhaus B, Ziemssen F, Bartz-Schmidt KU. Experimental implantation and long-term testing of an Intraocular Vision Aid in rabbits. Arch Ophthalmol 2005; 123: 964-969 [IF 3.274]
27.Warga M, Szurman P, Rohrbach JM. Karunkeltumor unklarer Dignität. Klin Monatsbl Augenheilkd 2005; 222: 733-735 [IF 0.412]
26.Jaissle GB, Szurman P, Bartz-Schmidt KU. Empfehlung für die Durchführung von intravitrealen Injektionen. Stellungnahme der Retinologischen Gesellschaft (RG), der Deutschen Ophthalmologischen Gesellschaft (DOG) und des Berufsverbandes der Augenärzte Deutschland (BVA). Klin Monatsbl Augenheilkd 2005; 222: 390-395 [IF 0.412]
25.Grisanti S, Szurman P, Warga M, Kaczmarek R, Ziemssen F, Tatar O, Bartz-Schmidt KU. Decorin modulates wound healing in experimental glaucoma filtration surgery: a pilot study. Invest Ophthalmol Vis Sci 2005; 46: 191-196 [IF 3.643]

2004

24.Grisanti S, Szurman P, Tatar O, Gelisken F, Aisenbrey S, Oficjalska-Mlynczak J, Kaczmarek R, Bartz-Schmidt KU. Histopathological analysis in experimental macular surgery with trypan blue. Br J Ophthalmol. 2004; 88: 1206-1208 [IF 2.495]
23.Grisanti S, Tatar O, Canbek S, Lafaut BA, Gelisken F, Inhoffen W, Szurman P, Aisenbrey S, Oficjalska-Mlynczak J, Bartz-Schmidt KU. Immunohistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy. Am J Ophthalmol 2004; 137: 914-23 [IF 2.332]
22.Grisanti S, Canbek S, Kaiserling E, Adam A, Lafaut B, Gelisken F, Szurman P, Henke-Fahle S, Oficjalska-Mlynczak J, Bartz-Schmidt KU. Expression of endoglin in choroidal neovascularization. Exp Eye Res 2004; 78: 207-213 [IF 2.846]
21.Roters S, Severin M, Konen W, Szurman P, Domarus D, Krieglstein GK. Contact lens, hyperopia and endothelial changes. Int Ophthalmol 2004; 25: 13-17
20.Grisanti S, Szurman P, Gelisken F, Aisenbrey S, Oficjalska-Mlynczak J, Bartz-Schmidt KU. Histological findings in experimental macular surgery with indocyanine green. Invest Ophthalmol Vis Sci 2004; 45: 282-286 [IF 3.577]
19.Rohrbach JM, Szurman P, Bartz-Schmidt KU. Augenverletzungen im Kindes- und Jugendalter. Klin Monatsbl Augenheilk 2004; 221:636-45 [IF 0.478]
18.Jaissle GB, Szurman P, Bartz-Schmidt KU. Nebenwirkungen und Komplikationen bei der intravitrealen Triamcinolonacetonid-Therapie. Ophthalmologe 2004; 101: 121-8 [IF 1.559]

2003

17.Aisenbrey S, Lafaut BA, Reynders S, Szurman P, Grisanti S, Van den Broecke C, Walter P, Bartz-Schmidt KU. Clinicopathological correlation of choroidal neovascularization after external beam radiotherapy in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2003; 241: 269-76  [IF 1.279]
16.Roters S, Hamzei P, Szurman P, Hermes S, Thumann G, Bartz-Schmdt KU, Kirchhof B. Combined penetrating keratoplasty and vitreoretinal surgery with silicone oil: a 1-year follow-up. Graefes Arch Clin Exp Ophthalmol 2003; 241: 24-33 [IF 1.279]
15.Szurman P, Pressler H, Kolb M, Rohrbach JM. “Maskerade-Fremdkörper“ in der Bindehaut. Klin Monatsbl Augenheilkd 2003; 220: 57-59 [IF 0.495]
14.Roters S, Szurman P, Hermes S, Thumann G, Bartz-Schmidt KU, Kirchhof B. Outcome of combined penetrating keratoplasty with vitreoretinal surgery for management of severe ocular injuries. Retina 2003; 23: 48-56 [IF 1.391]

2002

13.Aisenbrey S, Lafaut BA, Szurman P, Grisanti S, Lüke Ch, Krott R, Thumann G, Fricke J, Neugebauer A, Hilgers RD, Esser P, Walter P, Bartz-Schmidt KU. Macular translocation with 360° retinotomy for exudative age-related macular degeneration. Arch Ophthalmol 2002; 120: 451-459 [IF 2.337]
12.Roters S, Szurman P, Engels BF, Bartz-Schmidt KU, Krieglstein GK. Ultrasound biomicroscopy in chronic ocular hypotony: its impact on diagnosis and management. Retina. 2002; 22: 581-588 [IF 1.058]
11.Aisenbrey S, Lafaut BA, Szurman P, Grisanti S, Fricke J, Neugebauer A, Hilgers RD, Esser P, Walter P, Bartz-Schmidt KU. Makulatranslokation mit 360°-Retinotomie zur Behandlung der exsudativen Makuladegeneration. Functional and angiographic results. Ophthalmologe 2002; 99: 164-170 [IF 0.601]
10.Roters S, Hellmich M, Szurman P. Prediction of axial length on the basis of vitreous body length and lens thickness. Retrospective echobiometric study. J Cataract Refract Surg 2002; 28: 853-859 [IF 2.184]
9.Roters S, Engels BF, Szurman P, Krieglstein GK. Typical ultrasound biomicroscopic findings seen in ocular hypotony. Ophthalmologica 2002; 216: 90-95 [IF 0.647]
8.Grisanti S, Szurman P, Jordan J, Kociok N, Bartz-Schmidt KU, Heimann K. Xenotransplantation of retinal pigment epithelial cells into RCS rats. Jpn J Ophthalmol 2002; 46: 36-44 [IF 0.640]

2001

7.Roters S, Szurman P, Engels BF, Brunner R. The suitability of the ultrasound biomicroscope for establishing texture in giant cell arteritis. Br J Ophthalmol 2001; 85; 946-48 [IF 1.942]

2000

6.Szurman P, Di Tizio FM, Lafaut B, Aisenbrey S, Grisanti S, Roters S, Bartz-Schmidt KU. Stellenwert der postoperativen Positionierung in der Chirurgie des idiopathischen Makulaforamens - Kontrollierte konsekutive Studie. Klin Monatsbl Augenheilkd 2000; 217: 351-355 [IF 0.406]
5.Roters S, Szurman P. Elfjähriger atopischer Junge mit bislang therapieresistenter Keratokonjunctivitis. Ophthalmologe 2000; 97: 580-1 [IF 0.536]
4.Schraermeyer U, Kayatz P, Thumann G, Luther TT, Szurman P, Kociok N, Bartz-Schmidt KU. Transplantation of iris pigment epithelium into the choroid slows down the degeneration of photoreceptors in the RCS rat. Graefes Arch Clin Exp Ophthalmol 2000; 238: 979-84 [IF 1.112]
3.Szurman P, Bartz-Schmidt KU. Silikonöl in der Netzhautchirurgie. Ophthalmologe 2000; 97: 514-25 [IF 1.559]

1999

2.Walter P, Szurman P, Vobig M, Berk H, Lüdtke-Handjery HC, Richter H, Mittermayer C, Heimann K, Sellhaus B. Successful long-term implantation of electrically inactive epiretinal microelectrode arrays in rabbits. Retina 1999; 19: 546-552 [IF 0.751]

1998

1.Galal O, Abbag F, Fadley F, Redington A, Szurman P, Oufi S. Transcatheter closure of the patent duct as a day-case procedure. Cardiol Young 1995; 5: 48-50 [IF 0.912]